CN Patent

CN1331208A — 一种新的多肽——人肿瘤坏死因子受体21.45和编码这种多肽的多核苷酸

Assigned to Shanghai Biowindow Gene Development Inc · Expires 2002-01-16 · 24y expired

What this patent protects

本发明公开了一种新的多肽——人肿瘤坏死因子受体21.45,编码此多肽的多核苷酸和经DNA重组技术产生这种多肽的方法。本发明还公开了此多肽用于治疗多种疾病的方法,如各种肿瘤、炎症疾病等。本发明还公开了抗此多肽的拮抗剂及其治疗作用。本发明还公开了编码这种新的人肿瘤坏死因子受体21.45的多核苷酸的用途。

USPTO Abstract

本发明公开了一种新的多肽——人肿瘤坏死因子受体21.45,编码此多肽的多核苷酸和经DNA重组技术产生这种多肽的方法。本发明还公开了此多肽用于治疗多种疾病的方法,如各种肿瘤、炎症疾病等。本发明还公开了抗此多肽的拮抗剂及其治疗作用。本发明还公开了编码这种新的人肿瘤坏死因子受体21.45的多核苷酸的用途。

Drugs covered by this patent

bictegravir-sodium (BICTEGRAVIR SODIUM)

Patent Metadata

Patent number: CN1331208A
Jurisdiction: CN
Classification: —
Expires: 2002-01-16
Drug substance claim: No
Drug product claim: No
Assignee: Shanghai Biowindow Gene Development Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.